Reni Benjamin
Stock Analyst at JMP Securities
(1.43)
# 3,291
Out of 4,736 analysts
158
Total ratings
38.03%
Success rate
-12.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $112.89 | +10.73% | 19 | Jan 15, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $72.50 | - | 26 | Jan 14, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.37 | +191.97% | 5 | Jan 14, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $32 → $26 | $13.20 | +96.97% | 12 | Dec 18, 2024 | |
| STRO Sutro Biopharma | Reiterates: Market Outperform | $17 | $1.95 | +771.79% | 9 | Dec 11, 2024 | |
| PRLD Prelude Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.29 | +210.08% | 3 | Dec 11, 2024 | |
| LVTX LAVA Therapeutics | Downgrades: Market Perform | $6 | $0.95 | +531.58% | 6 | Dec 11, 2024 | |
| KURA Kura Oncology | Reiterates: Market Outperform | $32 | $7.27 | +340.17% | 8 | Nov 19, 2024 | |
| SANA Sana Biotechnology | Downgrades: Market Perform | n/a | $2.95 | - | 4 | Nov 5, 2024 | |
| TIL Instil Bio | Initiates: Market Perform | n/a | $19.40 | - | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $32 | $23.59 | +35.65% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $5 | $0.50 | +900.00% | 8 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $15 → $2 | $1.18 | +69.49% | 4 | Jul 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $14.23 | - | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $25 → $23 | $5.96 | +286.23% | 10 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.87 | - | 6 | Jan 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.94 | - | 3 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $4 | $2.31 | +73.54% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $4.40 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $5.16 | +229.78% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.64 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.40 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $7.49 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $3.05 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.56 | +2,742.42% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $16.17 | -38.16% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $29.51 | -59.34% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $10.23 | - | 1 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 2 | Nov 10, 2017 |
Blueprint Medicines
Jan 15, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $112.89
Upside: +10.73%
Incyte
Jan 14, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $72.50
Upside: -
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.37
Upside: +191.97%
Bicycle Therapeutics
Dec 18, 2024
Maintains: Market Outperform
Price Target: $32 → $26
Current: $13.20
Upside: +96.97%
Sutro Biopharma
Dec 11, 2024
Reiterates: Market Outperform
Price Target: $17
Current: $1.95
Upside: +771.79%
Prelude Therapeutics
Dec 11, 2024
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.29
Upside: +210.08%
LAVA Therapeutics
Dec 11, 2024
Downgrades: Market Perform
Price Target: $6
Current: $0.95
Upside: +531.58%
Kura Oncology
Nov 19, 2024
Reiterates: Market Outperform
Price Target: $32
Current: $7.27
Upside: +340.17%
Sana Biotechnology
Nov 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $2.95
Upside: -
Instil Bio
Nov 4, 2024
Initiates: Market Perform
Price Target: n/a
Current: $19.40
Upside: -
Nov 4, 2024
Initiates: Market Outperform
Price Target: $32
Current: $23.59
Upside: +35.65%
Sep 16, 2024
Reiterates: Market Outperform
Price Target: $5
Current: $0.50
Upside: +900.00%
Jul 26, 2024
Maintains: Market Outperform
Price Target: $15 → $2
Current: $1.18
Upside: +69.49%
Jul 23, 2024
Initiates: Market Perform
Price Target: n/a
Current: $14.23
Upside: -
Jun 20, 2024
Maintains: Market Outperform
Price Target: $25 → $23
Current: $5.96
Upside: +286.23%
Jan 5, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.87
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.94
Upside: -
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $2.31
Upside: +73.54%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $4.40
Upside: -
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $5.16
Upside: +229.78%
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.64
Upside: -
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $2.40
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $7.49
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $3.05
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.56
Upside: +2,742.42%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $16.17
Upside: -38.16%
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $29.51
Upside: -59.34%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $10.23
Upside: -
Nov 10, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -